Editor's Note: This interview was recorded on August 27, 2016, at the European Society of Cardiology (ESC) conference in Rome.
E. Magnus Ohman, MD: Hello. I'm Magnus Ohman, and I'm here with Professor Tom Lüscher, a cardiologist from Switzerland. But for most of the audience, you probably know of him as the editor-in-chief of the European Heart Journal—a very prominent journal in the field of cardiovascular medicine. Welcome to the program.
Thomas F. Lüscher, MD, FRCP: Thank you for having me.
Dr Ohman: The journal has taken off in such a dramatic way over the past several years since you took on the editorship. It would be interesting for people to know [about this], because most physicians when going to medical school really do not start thinking about running a medical journal. Somewhere along the way, you must have had some interest in this area.
But before we get into that, it has only been about 8 years [since you became the editor]. Tell us a little bit about your background, where you were born, and a little bit about your family.
Philosophy, Science, and Tragedy
Dr Lüscher:I was born in Zurich and raised in a doctor's family.
Trans Women in Female Sports: A Sports Scientist's Take
Hormones for Gender Dysphoria Associated With Cardiovascular Risk
Takotsubo Syndrome Also Linked to Happy Life Events
Cardiac Arrest Centers No Benefit in OHCA Without STEMI
COMMENTARY
Life and Times of Leading Cardiologists: Thomas Lüscher
Interviewer: E. Magnus Ohman, MD; Interviewee: Thomas F. Lüscher, MD, FRCP
DisclosuresDecember 07, 2016
Editor's Note: This interview was recorded on August 27, 2016, at the European Society of Cardiology (ESC) conference in Rome.
E. Magnus Ohman, MD: Hello. I'm Magnus Ohman, and I'm here with Professor Tom Lüscher, a cardiologist from Switzerland. But for most of the audience, you probably know of him as the editor-in-chief of the European Heart Journal—a very prominent journal in the field of cardiovascular medicine. Welcome to the program.
Thomas F. Lüscher, MD, FRCP: Thank you for having me.
Dr Ohman: The journal has taken off in such a dramatic way over the past several years since you took on the editorship. It would be interesting for people to know [about this], because most physicians when going to medical school really do not start thinking about running a medical journal. Somewhere along the way, you must have had some interest in this area.
But before we get into that, it has only been about 8 years [since you became the editor]. Tell us a little bit about your background, where you were born, and a little bit about your family.
Philosophy, Science, and Tragedy
Dr Lüscher:I was born in Zurich and raised in a doctor's family.
© 2016 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Life and Times of Leading Cardiologists: Thomas Lüscher - Medscape - Dec 07, 2016.
Tables
References
Authors and Disclosures
Authors and Disclosures
Interviewer
E. Magnus Ohman, MD
Professor of Medicine, Division of Cardiovascular Medicine; Vice-Chair, Department of Medicine, Development and Innovation, Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease; Associate Director, Duke Heart Center, Duke University Medical Center, Durham, North Carolina
Disclosure: E. Magnus Ohman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: ABIOMED; AstraZeneca Pharmaceuticals LP; Biotie Therapies; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Faculty Connection, LLC; Stealth Peptides; The Medicines Company; Medscape
Received research grant from: Daiichi Sankyo; Gilead Sciences Inc; Janssen Pharmaceutical Products, LP
Received income in an amount equal to or greater than $250 from: ABIOMED; AstraZeneca Pharmaceuticals LP; Biotie Therapies; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Faculty Connection, LLC; Gilead Sciences Inc; Janssen Pharmaceutical Products, LP; Stealth Peptides; The Medicines Company; Medscape
Interviewee
Thomas F. Lüscher, MD, FRCP
Professor and Chairman of Cardiology, Department of Cardiology; Head, University Heart Center, University Hospital Zurich, Zurich, Switzerland
Disclosure: Thomas F. Lüscher, MD, FRCP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Merck Sharp & Dohme Corp.
Received research grant from: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; BIOTRONIK; Biosensors International Group, Ltd.; Boston Scientific; Daiichi Sankyo, Inc.; Eli Lilly and Company; Edwards Lifesciences; Merck & Co., Inc.; Pfizer, Inc.; Roche; Roche Diagnostics; SERVIER; Sorin Group
Received income in an amount equal to or greater than $250 from: Amgen Inc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Daiichi Sankyo; Eli Lilly and Company; Merck & Co.; Pfizer, Inc.; Roche; sanofi-aventis; SERVIER; St. Jude Medical
Received educational grants from: Actelion Pharmaceuticals, Ltd; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; The Medicines Company; Menarini Group; Novartis Pharmaceuticals Corporation; Pfizer Schweiz; St. Jude Medical